Welcome to Idorsia

Positive results in second
pivotal study with
daridorexant for
patients with
insomnia

Annual Report

Our 2019 report
consists of three
books

There’s more to Idorsia
than meets the eye!

Read the interview with
our CEO & CSO to get to
the bottom of the story...

Our key assets have
the potential to
transform treatment in
the target indications...

The purpose of Idorsia is to discover, develop and bring more, innovative medicines to patients.

Idorsia’s success depends on its people.

Idorsia's development compounds target a number of different diseases.

06 Jul 2020	Idorsia announces positive results in the second Phase 3 study of daridorexant
20 May 2020	Idorsia successfully completes the offering of new shares thereby securing funding for the company’s growth plan
19 May 2020	Idorsia launches an offering of new shares to fund the company’s growth plan

Event	When
Half-Year 2020 Financial Results reporting*	July 23, 2020
Nine-months 2020 Financial Results reporting*	October 22, 2020
Full year 2020 Financial Results reporting*	February 4, 2021

*We will be in a silent period for 10 days ahead of the financial reporting.

IDIA SIX Swiss Exchange

At 17:31:45 CET

31.34 CHF

-1.02 (-3.15 %)

Idorsia Pharmaceuticals Ltd

Hegenheimermattweg 91

4123 Allschwil

Switzerland